Jiangsu Recbio Biotechnology Co., LTD. ( "Recbio" or "Company", Stock Code: 02179.HK) which founded in 2011, is an innovative vaccine company with independent research and development technology as the core driving force. Recbio is committed to building a full value chain of innovative vaccines covering R&D, production and commercialization. For a long time, the company always uphold the "Protect Human Health with Best-in-Class Vaccines" mission, with the evaluation of novel adjuvants, protein engineering, immune strong research and development of the engine, core technology platform through strategic focus has significant burden of disease areas, building is composed of many blockbuster with independent intellectual property rights of vaccine of high value product line, to address public health needs that are far from being met.